Australian Chemicals Stock News

Westpac Banking (ASX:WBC) is back in the spotlight after a rare governance protest vote, renewed pressure over its fossil fuel lending, and a recent eftpos outage that briefly disrupted thousands of customers. See our latest analysis for Westpac Banking. Despite this mix of governance tension, climate scrutiny and operational hiccups, Westpac’s A$38.26 share price still sits on a robust year to date share price return of 18.05 percent, underpinned by a strong 1 year total shareholder return...

Investor chatter around Lynas Rare Earths (ASX:LYC) has picked up after Morningstar tagged the stock as overpriced unless rare earth prices climb sharply, at the same time as operational disruption and index profile headlines complicate the outlook. See our latest analysis for Lynas Rare Earths. Those concerns have landed just as the share price has cooled off, with a 7 day share price return of minus 9.51 percent and 30 day share price return of minus 10.97 percent following director share...

Earlier this week, James Hardie Industries appointed Jonathan Skelly as President and General Manager of its North America Building Products Group and promoted long-time executive John Madson to Chief Sales Officer, while North America President Sean Gadd chose to leave the company. The leadership reshuffle hands James Hardie’s largest market to an external hire with deep experience at AZEK and Grainger, paired with an insider sales leader who has spent over two decades building the firm’s...

In recent weeks, Fortescue Ltd expanded its green technology push by partnering with Taiyuan Iron and Steel Group on hydrogen-based plasma-enhanced low‑carbon steelmaking, while also updating investors at the Resourcing Tomorrow conference in London and issuing new employee incentive securities. Together with its latest Modern Slavery Statement and strengthened supply chain standards, these moves highlight Fortescue’s attempt to align long-term growth with decarbonisation and human rights...

Greenhy2 Limited ( ASX:H2G ) insiders who bought shares over the past year were rewarded handsomely last week. The...

Key Insights Using the 2 Stage Free Cash Flow to Equity, NRW Holdings fair value estimate is AU$8.94 Current share...

Australian shares are poised for a robust start, with a projected 0.75% increase following the Federal Reserve's decision to trim U.S. rates for the third consecutive time. In this context, penny stocks—despite their somewhat outdated moniker—remain an intriguing investment area due to their potential for significant returns when backed by solid financials. This article explores three ASX penny stocks that exhibit strong financial foundations and could offer investors hidden value and growth...

With its stock down 16% over the past three months, it is easy to disregard Objective (ASX:OCL). But if you pay close...

Hazer Group Limited ( ASX:HZR ) shareholders should be happy to see the share price up 12% in the last quarter. But...

SGH Limited ( ASX:SGH ) received a lot of attention from a substantial price movement on the ASX over the last few...

QBE Insurance Group has recently tightened climate requirements for its oil and gas clients, advanced its net zero commitments, continued expanding leadership in its UK casualty business, issued and converted 3,845 new ordinary shares, and announced that Non-Executive Director Peter Wilson will leave the board at the end of 2025 to join a competitor. Together, these moves highlight QBE’s push to sharpen climate risk oversight, deepen specialist underwriting capability in key markets, and...

CSL recently reported five-year Phase 3 HOPE-B data in NEJM and at the ASH meeting, showing HEMGENIX’s durable factor IX activity, sustained bleed reduction, and continued freedom from routine prophylaxis in adults with hemophilia B. The results reinforce HEMGENIX’s position as the only commercially available gene therapy for adult hemophilia B, with long-term safety and efficacy data that may shape how patients and clinicians view one-time gene therapy versus ongoing prophylaxis. We’ll now...

With a price-to-sales (or "P/S") ratio of 3.3x Raiz Invest Limited ( ASX:RZI ) may be sending very bullish signals at...

When close to half the companies operating in the Consumer Services industry in Australia have price-to-sales ratios...

We wouldn't blame Catalyst Metals Limited ( ASX:CYL ) shareholders if they were a little worried about the fact that...

Most readers would already be aware that Whitehaven Coal's (ASX:WHC) stock increased significantly by 21% over the past...

Key Insights Tesoro Gold's significant individual investors ownership suggests that the key decisions are influenced by...

Clinuvel Pharmaceuticals (ASX:CUV) is in the spotlight after unveiling a major expansion of its Vallaurix innovation hub in Singapore. The company has announced a five year push backed by the Economic Development Board to accelerate advanced peptide drug development. See our latest analysis for Clinuvel Pharmaceuticals. The market seems to be warming to that strategy, with a 30 day share price return of 17.15% and a 90 day gain of 21.11%. However, the five year total shareholder return...

Champion Iron's (ASX:CIA) stock is up by a considerable 35% over the past three months. However, we wonder if the...

Some Kip McGrath Education Centres Limited ( ASX:KME ) shareholders may be a little concerned to see that insider Storm...

Insiders who bought Cryosite Limited ( ASX:CTE ) in the last 12 months may probably not pay attention to the stock's...

Key Insights The considerable ownership by individual investors in Prospect Resources indicates that they collectively...

Anyone interested in Imdex Limited ( ASX:IMD ) should probably be aware that the Independent Non-Executive Chairman...

Investors may wish to note that the Non Executive Independent Chairman of Beforepay Group Limited , Brian Hartzer...